Enlicitide Decanoate: Molecular Structure

Molecular Structure#

Enlicitide decanoate (MK-0616) is a macrocyclic peptide that represents a breakthrough in the application of constrained peptide chemistry to oral drug design. Developed by Merck, the molecule was designed to recapitulate the PCSK9-neutralizing activity of monoclonal antibodies in a molecule small enough for oral absorption.

The molecule is a 14-residue cyclic peptide incorporating multiple noncanonical amino acids and N-methylated peptide bonds. The "decanoate" designation refers to a decanoic acid (C10 fatty acid) conjugation that enhances the molecule's lipophilicity and oral absorption properties. The macrocyclic ring is closed via a thioether bond, providing a stable covalent linkage resistant to reduction under physiological conditions.

Design Principles#

Enlicitide was designed using structure-guided medicinal chemistry approaches:

1. Macrocyclic constraint: Cyclization locks the peptide into a bioactive conformation that mimics a key epitope on the LDLR surface, enabling competitive binding to PCSK9
2. N-methylation: Strategic methylation of backbone amide nitrogens reduces hydrogen bond donor count, enhancing cell membrane permeability and oral absorption
3. Noncanonical amino acids: Unnatural residues confer resistance to pancreatic and hepatic proteases, extending gastrointestinal survival
4. Decanoic acid conjugation: The C10 fatty acid chain increases lipophilicity, promotes interaction with lipid membranes, and may facilitate transcellular absorption
5. Fluorine incorporation: A fluorine atom in the structure optimizes metabolic stability and binding interactions

Chemical Properties#

Pharmacology#

Target Binding#

Enlicitide binds to the LDL receptor-binding domain of PCSK9 with an IC50 of 2.5 nM. The macrocyclic peptide mimics a structural epitope on the LDL receptor surface, acting as a molecular decoy that competitively prevents PCSK9 from engaging and degrading LDL receptors.

This binding site overlap means that enlicitide and the LDLR compete for the same surface on PCSK9. When enlicitide occupies this site, PCSK9 cannot bind to LDLR, and the receptor is free to recycle to the hepatocyte surface for additional rounds of LDL clearance.

Pharmacodynamics#

The pharmacodynamic cascade following PCSK9 inhibition by enlicitide:

• PCSK9 neutralization reduces LDLR degradation
• More LDL receptors are expressed on hepatocyte surfaces
• Hepatic LDL cholesterol uptake increases
• Circulating LDL-C decreases (55-60% in clinical trials)
• Secondary reductions in apolipoprotein B, non-HDL-C, and lipoprotein(a)

Pharmacokinetics#

Enlicitide was designed for once-daily oral administration at 20 mg:

• Oral absorption: Facilitated by macrocyclic design and decanoic acid conjugation
• Fasting administration: Phase 2b protocol specified dosing 30 minutes before meals
• Protease resistance: Noncanonical amino acids and N-methylation confer stability in the GI tract
• Dose proportionality: Demonstrated across the 6-30 mg dose range in Phase 2b

Stability#

Enlicitide has been formulated as an oral solid dosage form (tablet), confirming adequate chemical and physical stability for manufacturing and distribution. Key stability features include:

• The thioether cyclization is more stable than disulfide bonds under reducing conditions
• N-methylated peptide bonds resist enzymatic hydrolysis
• The macrocyclic conformation buries vulnerable amide bonds within the ring interior
• Decanoic acid conjugation enhances stability against aminopeptidases

Comparison with Injectable PCSK9 Inhibitors#

Structure-Activity Relationships#

The development of enlicitide required solving several key structure-activity challenges:

• Ring size optimization: The 14-residue macrocycle provides sufficient surface area for high-affinity PCSK9 binding while remaining small enough for oral absorption
• N-methylation pattern: Each methylation site was optimized individually to balance permeability gain against potential loss of target binding
• Fatty acid selection: Decanoic acid (C10) was selected over shorter and longer chain lengths based on the optimal balance of lipophilicity for absorption and aqueous solubility for dissolution
• Thioether vs disulfide: The irreversible thioether cyclization was chosen over a reversible disulfide to prevent ring opening under reducing gastrointestinal conditions

Related Reading#

• Enlicitide overview and research guide
• Peptides similar to Enlicitide
• Enlicitide research evidence